| 1 | 1 | | SR0737LRB103 39201 MST 69348 r SR0737 LRB103 39201 MST 69348 r |
|---|
| 2 | 2 | | SR0737 LRB103 39201 MST 69348 r |
|---|
| 3 | 3 | | 1 SENATE RESOLUTION |
|---|
| 4 | 4 | | 2 WHEREAS, Cholangiocarcinoma (bile duct cancer) is a rare |
|---|
| 5 | 5 | | 3 form of cancer that originates from the cells lining the bile |
|---|
| 6 | 6 | | 4 ducts that play a key role in digestion; there are three types |
|---|
| 7 | 7 | | 5 of this cancer, intrahepatic, extrahepatic, and perihilar; and |
|---|
| 8 | 8 | | 6 WHEREAS, Approximately 12,000 Americans are diagnosed each |
|---|
| 9 | 9 | | 7 year with cholangiocarcinoma, with numbers increasing yearly, |
|---|
| 10 | 10 | | 8 and the mortality rate has increased dramatically in the last |
|---|
| 11 | 11 | | 9 decade; and |
|---|
| 12 | 12 | | 10 WHEREAS, Patients are typically diagnosed at a late stage |
|---|
| 13 | 13 | | 11 due to the lack of a validated early method of detection; |
|---|
| 14 | 14 | | 12 symptoms of jaundice, abdominal pain, itchy skin, and weight |
|---|
| 15 | 15 | | 13 loss are symptoms that do not usually present until advanced |
|---|
| 16 | 16 | | 14 disease progression; and |
|---|
| 17 | 17 | | 15 WHEREAS, Cholangiocarcinoma is a rare cancer; of the top |
|---|
| 18 | 18 | | 16 eight deadliest cancers, seven are rare; rare cancers have a |
|---|
| 19 | 19 | | 17 five-year survival rate under 50%, with the cholangiocarcinoma |
|---|
| 20 | 20 | | 18 five-year survival rate being approximately 20%; and |
|---|
| 21 | 21 | | 19 WHEREAS, There is currently no cure for |
|---|
| 22 | 22 | | 20 cholangiocarcinoma/bile duct cancer; and |
|---|
| 23 | 23 | | |
|---|
| 24 | 24 | | |
|---|
| 25 | 25 | | |
|---|
| 26 | 26 | | SR0737 LRB103 39201 MST 69348 r |
|---|
| 27 | 27 | | |
|---|
| 28 | 28 | | |
|---|
| 29 | 29 | | SR0737- 2 -LRB103 39201 MST 69348 r SR0737 - 2 - LRB103 39201 MST 69348 r |
|---|
| 30 | 30 | | SR0737 - 2 - LRB103 39201 MST 69348 r |
|---|
| 31 | 31 | | 1 WHEREAS, Kelly green is the color representing |
|---|
| 32 | 32 | | 2 cholangiocarcinoma/bile duct cancer awareness; and |
|---|
| 33 | 33 | | 3 WHEREAS, Foundations, research and teaching hospitals, |
|---|
| 34 | 34 | | 4 rare cancer advocate groups, and patient advocate groups from |
|---|
| 35 | 35 | | 5 around the globe have joined together to recognize February |
|---|
| 36 | 36 | | 6 18, 2024 as World Cholangiocarcinoma Day; and |
|---|
| 37 | 37 | | 7 WHEREAS, Increased cholangiocarcinoma advocacy, |
|---|
| 38 | 38 | | 8 awareness, research, and education will bring improved |
|---|
| 39 | 39 | | 9 outcomes for patients in earlier detection and treatment and |
|---|
| 40 | 40 | | 10 potential curative methods; therefore, be it |
|---|
| 41 | 41 | | |
|---|
| 42 | 42 | | |
|---|
| 43 | 43 | | |
|---|
| 44 | 44 | | |
|---|
| 45 | 45 | | |
|---|
| 46 | 46 | | SR0737 - 2 - LRB103 39201 MST 69348 r |
|---|